Is VRNA a good stock to buy?

Advice: Based on the provided data and current market conditions, it is not advisable to invest in Verona Pharma (VRNA) at this time.Analysis:1. P/E Ratio: A negative P/E ratio of -23.4 indicates that the company is currently generating losses, which is a red flag for potential investors.2. P/S Ratio: The lack of a P/S ratio suggests that the company's revenue is not significant enough to warrant consideration.3. Market Capitalization: With a market capitalization of $1.27 billion, Verona Pharma is a relatively large company. However, this alone does not guarantee investment suitability.4. Revenue Growth Rate: A -100% year-on-year revenue growth rate raises concerns about the company's ability to generate sustainable returns.5. Stock Performance: The closing price of $15.71 and a recent percentage change of -2.24% indicate volatility and potential downside risk.Conclusion: Given the negative P/E ratio, lack of revenue, and significant revenue decline, investing in Verona Pharma (VRNA) at this time carries a high risk. The company's current financial health and market performance do not support a strong investment case. Investors should consider alternative opportunities with more promising fundamentals.${富文本块}${富文本块}${富文本块}${富文本块}